Risk, returns & timeframes illustration
1 min read
May 1, 2023
by
Regan Pearson

Big tech earnings were a snack. What’s next? 🍟

Who’s FAANGING now? Big Tech may have prepared for an economic slowdown and volatility by slimming down staff, but earnings results were still full of small surprises. Seems slight growth in revenue won against growing global competition for eyeballs. But they’re still battening down the hatches ready to weather any storms ahead.
1 min read
May 1, 2023
by
Regan Pearson

Big tech earnings were a snack. What’s next? 🍟

Who’s FAANGING now? Big Tech may have prepared for an economic slowdown and volatility by slimming down staff, but earnings results were still full of small surprises. Seems slight growth in revenue won against growing global competition for eyeballs. But they’re still battening down the hatches ready to weather any storms ahead.
1 min read
May 1, 2023
by
Regan Pearson

Big tech earnings were a snack. What’s next? 🍟

Who’s FAANGING now? Big Tech may have prepared for an economic slowdown and volatility by slimming down staff, but earnings results were still full of small surprises. Seems slight growth in revenue won against growing global competition for eyeballs. But they’re still battening down the hatches ready to weather any storms ahead.
Table of contents
Getting Started Investing course
Free Getting Started Course
Take your first, or next, step to becoming a confident investor with Hatch's free online course – just 10 minutes a day, for 10 days.

Trying to fill our secret snack cupboards is getting harder as inflation bites (although we’re all aboard L&P gummies). But employees at Alphabet’s Google (GOOGL, GOOG) are also about to find it harder to get their snack fix. Despite having 12,000 fewer mouths to feed, in an effort to cut costs, Google is slimming down the snacks, including the dried mango and fun-sized M&Ms. 🥭

Big Tech companies moved early to slash costs ahead of a potential economic downturn. But to the surprise of many investors the cupboards haven't gone bare just yet. Last week Alphabet and Microsoft (MSFT) announced snack-sized revenue growth of 3% and of 7% respectively year-on-year for the first quarter. Meanwhile Meta (META) said Chinese retailers helped their revenue in the first quarter of 2023 grow a tasty 3%, reversing declines in revenue endured in 2022. That hit the sweet spot for investors, who sent the company’s share price spiking almost 20%. 🍬

The better-than-expected tech earnings has been a bitter pill for those betting against the companies’ share prices, however. According to the Financial Times, hedge funds have lost US$18 billion this year betting that share prices of Big Tech would continue their downward slide. 💸

So what’s next for Big Tech and FAANG stocks? While downsizing snacks and costs, and upsizing investment in AI has been a theme across the behemoth tech companies, another big theme was ‘uncertainty’. Alphabet noted on their earnings call that ‘the outlook remains uncertain’ as they face a double whammy of slowing ad revenue and gnawing competition from TikTok on their YouTube business. While Meta called out ‘a volatile macro environment’ for the year ahead. 🥠

One of the saltiest outlooks came from Netflix (NFLX), however, which lowered expectations for earnings for the quarter ahead, and declined to offer guidance on subscriber numbers. Let’s hope their snack cupboard is filled with more than just recession lentils. 🍿

Regan Pearson
Finance writer
Linkedin

We’re not financial advisors and Hatch news is for your information only. However dazzling our writing, none of it is a recommendation to invest in any of the companies or funds mentioned. If you want support before making any investment decisions, consider seeking financial advice from a licensed provider. We’ve done our best to ensure all information is current when we pushed ‘publish’ on this article. And of course, with investing, your money isn’t guaranteed to grow and there’s always a risk you might lose money.

Join the Kiwis who are hatching their tomorrow and have invested more than $1 billion with Hatch.

Explore another series
Tax
Money
Economy
Investing

More recent news articles

Recent learn articles

7 min read
Apr 15, 2025

EV market rising but Tesla sales decline

Predicted by some to become a US $1.58 trillion dollar market globally, in the US alone EV sales are up 11.4% year-over-year. Which countries are leading the fast-charge? And how could trade tariffs impact sales as we accelerate into the second quarter?
Read more
8 min read
Mar 25, 2025

What’s driving gold prices to record highs?

As the world waits for Trump’s tariffs policies to take effect, the allure of gold has sent bullion, stocks and ETFs to glittering highs. But could gold’s volatility and the potential for the US to sell its gold reserves to buy bitcoin prime other global central banks to do the same?
Read more
8 min read
Mar 4, 2025

Can Biotech beat cancer?

Some Kiwi companies are making significant advances in cancer diagnosis and treatment that could save lives worldwide. Global pharmaceutical companies are also making huge strides in cancer clinical trials, but could Trump’s administration derail decades of research?
Read more

Related news articles

More recent learn articles

No items found.

Recent news articles

More recent learn articles

7 min read
Apr 15, 2025

EV market rising but Tesla sales decline

Predicted by some to become a US $1.58 trillion dollar market globally, in the US alone EV sales are up 11.4% year-over-year. Which countries are leading the fast-charge? And how could trade tariffs impact sales as we accelerate into the second quarter?
Read more
8 min read
Mar 25, 2025

What’s driving gold prices to record highs?

As the world waits for Trump’s tariffs policies to take effect, the allure of gold has sent bullion, stocks and ETFs to glittering highs. But could gold’s volatility and the potential for the US to sell its gold reserves to buy bitcoin prime other global central banks to do the same?
Read more
8 min read
Mar 4, 2025

Can Biotech beat cancer?

Some Kiwi companies are making significant advances in cancer diagnosis and treatment that could save lives worldwide. Global pharmaceutical companies are also making huge strides in cancer clinical trials, but could Trump’s administration derail decades of research?
Read more